CD274 and non-small cell lung carcinoma: Promising data from studies such as IMpower-010, and KEYNOTE-091/PEARLS have driven the incorporation of adjuvant atezolizumab and pembrolizumab in the NCCN guidelines for patients with resected stage II-IIIA NSCLC who exhibit PD-L1 expression of ≥1% following chemotherapy.3 The IMpower-010 study showed an apparent improvement on disease-free survival (DFS) with adjuvant atezolizumab.